Utilization of kinase inhibitors as novel therapeutic drug targets: A review

被引:14
作者
Nishal, Suchitra [1 ]
Jhawat, Vikas [1 ]
Gupta, Sumeet [2 ]
Phaugat, Parmita [1 ]
机构
[1] GD Goenka Univ, Sch Med & Allied Sci, Dept Pharm, Gurugram, India
[2] Maharishi Markandeshwar Deemed Univ, Dept Pharmaceut Sci, Ambala, Haryana, India
关键词
Kinase inhibitors; Targeted; Drug designing; Anti-cancer; Auto-immune diseases; PLECKSTRIN HOMOLOGY DOMAIN; POTENT INHIBITOR; PROTEIN-KINASES; BLOOD-PRESSURE; ABL KINASE; IN-VITRO; BCR-ABL; MOLECULE; CANCER; DISCOVERY;
D O I
10.32604/or.2022.027549
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Kinase inhibitors are a significant and continuously developing division of target therapeutics. The drug discovery and improvement efforts have examined numerous attempts to target the signaling pathway of kinases. The Kinase inhibitors have been heralded as a game-changer in cancer treatment. For developing kinase inhibitors as a treatment for various non-malignant disorders like auto-immune diseases, is currently undergoing extensive research. It may be beneficial to investigate whether cell-specific kinase inhibitor administration enhances therapeutic efficacy and decreases adverse effects. The goal of the current review is to gain insight into the role of kinase inhibitors in facilitating effective target drug delivery for the treatment of various anti-inflammatory, auto-immune, and anticancer disorders. The aim of this review is also to shed light on drug discovery approaches for kinase inhibitors, their mode of action, and delivery approaches. The variation in the binding of kinases bestows different target approaches in drug design, which can be employed for designing the targeted molecules. Several target sites have been studied, exceeding the design of drugs for various diseases like cancer, Alzheimer's, rheumatoid arthritis, etc. Diverse delivery approaches have also been studied for the targeted application of kinase inhibitors.
引用
收藏
页码:221 / 230
页数:10
相关论文
共 98 条
[11]  
Bikker JA, 2011, RSC DRUG DISCOV, V19, P126, DOI 10.1039/9781849733557-00126
[12]   Identification of a pocket in the PDK1 kinase domain that interacts with PIF and the C-terminal residues of PKA [J].
Biondi, RM ;
Cheung, PCF ;
Casamayor, A ;
Deak, M ;
Currie, RA ;
Alessi, DR .
EMBO JOURNAL, 2000, 19 (05) :979-988
[13]   Radioactive 198Au-Doped Nanostructures with Different Shapes for In Vivo Analyses of Their Biodistribution, Tumor Uptake, and Intratumoral Distribution [J].
Black, Kvar C. L. ;
Wang, Yucai ;
Luehmann, Hannah P. ;
Cai, Xin ;
Xing, Wenxin ;
Pang, Bo ;
Zhao, Yongfeng ;
Cutler, Cathy S. ;
Wang, Lihong V. ;
Liu, Yongjian ;
Xia, Younan .
ACS NANO, 2014, 8 (05) :4385-4394
[14]   Comparative Assessment of Protein Kinase Inhibitors in Public Databases and in PKIDB [J].
Bournez, Colin ;
Carles, Fabrice ;
Peyrat, Gautier ;
Aci-Seche, Samia ;
Bourg, Stephane ;
Meyer, Christophe ;
Bonnet, Pascal .
MOLECULES, 2020, 25 (14)
[15]   WNK-SPAK/OSR1-NCC kinase signaling pathway as a novel target for the treatment of salt-sensitive hypertension [J].
Brown, Archie ;
Meor Azlan, Nur Farah ;
Wu, Zhijuan ;
Zhang, Jinwei .
ACTA PHARMACOLOGICA SINICA, 2021, 42 (04) :508-517
[16]   PKIDB: A Curated, Annotated and Updated Database of Protein Kinase Inhibitors in Clinical Trials [J].
Carles, Fabrice ;
Bourg, Stephane ;
Meyer, Christophe ;
Bonnet, Pascal .
MOLECULES, 2018, 23 (04)
[17]  
Cheung CHA, 2009, EXPERT OPIN INV DRUG, V18, P379, DOI [10.1517/13543780902806392 , 10.1517/13543780902806392]
[18]   Arctigenin, a phenylpropanoid dibenzylbutyrolactone lignan, inhibits MAP kinases and AP-1 activation via potent MKK inhibition:: the role in TNF-α inhibition [J].
Cho, MK ;
Jang, YP ;
Kim, YC ;
Kim, SG .
INTERNATIONAL IMMUNOPHARMACOLOGY, 2004, 4 (10-11) :1419-1429
[19]   Structure of the FKBP12-rapamycin complex interacting with the binding domain of human FRAP [J].
Choi, JW ;
Chen, J ;
Schreiber, SL ;
Clardy, J .
SCIENCE, 1996, 273 (5272) :239-242
[20]   Protein kinases - the major drug targets of the twenty-first century? [J].
Cohen, P .
NATURE REVIEWS DRUG DISCOVERY, 2002, 1 (04) :309-315